Regulation - Regulation, Nephrology and Hepatology

Filter

Popular Filters

26 to 41 of 41 results

Keryx Biopharma rockets on new Zerenex data and plans to file for approval

29-01-2013

USA-based Keryx Biopharmaceuticals (Nasdaq: KERX) saw its shares close up a whopping 77% to $4.70 in…

BiotechnologyKeryx BiopharmaceuticalsNephrology and HepatologyPharmaceuticalRegulationRenagelRenvelaResearchSanofiZerenex

Novartis' Votubia cleared for non-cancerous kidney tumors in EU

05-11-2012

Swiss drug major Novartis' (NOVN: VX) shares rose 1.1% this morning, as the company revealed it has received…

EuropeNephrology and HepatologyNovartisPharmaceuticalRegulationVotubia

AVEO and Astellas file NDA for tivozanib in kidney cancer

02-10-2012

USA-based AVEO Oncology (Nasdaq: AVEO) and Japanese drug major Astellas Pharma (TSE:4503) have submitted…

Astellas PharmaAVEO OncologyBiotechnologyNephrology and HepatologyNorth AmericaOncologyPharmaceuticalRegulationtivozanib

Japanese filings for Shionogi's metreleptin and Otsuka's tolvaptin

06-08-2012

Japanese drugmaker Shionogi (TYO: 4507) said last week that it has filed a New Drug Application with…

Asia-PacificmetreleptinNephrology and HepatologyOtsukaPharmaceuticalRare diseasesRegulationSamscaShionogitolvaptin

Regulatory filing preparations underway for Vifor's PA21 on good Ph III results

09-07-2012

The pivotal Phase III clinical study shows that the new phosphate binder PA21 successfully controls hyperphosphatemia…

FreseniusGalenicaNephrology and HepatologyPA21PharmaceuticalRegulationResearchVifor Pharma

Affymax and Takeda get special Medicare code for Omontys

16-04-2012

USA-based Affymax (Nasdaq: AFFY) and the US subsidiary of Japanese drug major Takeda Pharmaceuticals…

AffymaxBiotechnologyNephrology and HepatologyNorth AmericaOmontysOncologypeginesatidePharmaceuticalPricingRegulationTakeda Pharmaceuticals

Promethera raises 23.6 million euros, with backers including Shire and Boehringer

28-03-2012

Belgian cell therapy company Promethera Biosciences yesterday completed a fundraising round that generated…

BiotechnologyBoehringer IngelheimFinancialHepaStemNephrology and HepatologyPromethera BiosciencesRegulationShire

FDA backs Affymax and Takeda drug Omontys for anemia due to CKD

28-03-2012

The US Food and Drug Administration yesterday approved Omontys (peginesatide, formerly known as Hematide)…

AffymaxBiotechnologyNephrology and HepatologyNorth AmericaOmontyspeginesatidePharmaceuticalRegulationTakeda Pharmaceuticals

US FDA mixed views on Vytorin and Zetia

26-01-2012

US drug giant Merck & Co (NYSE: MRK) yesterday received Food and Drug Administration approval to update…

Cardio-vascularMerck & CoNephrology and HepatologyNorth AmericaPharmaceuticalRegulationVytorinZetia

BTG’s Voraxaze gains first approval, in USA

19-01-2012

The US Food and Drug Administration has approved UK headquartered BTG International’s (LSE: BGC)…

BiotechnologyBTGNephrology and HepatologyNorth AmericaOncologyRegulationVoraxaze

AVEO and Astellas’ tivozanib beats sorafenib in Ph III TIVO-1 trial

04-01-2012

US cancer drug developer AVEO Pharmaceuticals (Nasdaq: AVEO)) and partner Japanese drug major Astellas…

Astellas PharmaAVEO PharmaceuticalsBayerBiotechnologyNephrology and HepatologyNexavarOncologyPharmaceuticalRegulationResearchtivozanib

Isis sees Kynamro delay; adds new drugs to pipeline

15-12-2011

California, USA-based Isis Pharmaceuticals (Nasdaq: ISIS) announced yesterday that there will be a slight…

Cardio-vascularGenzymeIsis PharmaceuticalsKynamromipomersenNephrology and HepatologyPharmaceuticalRegulationResearchSanofi

FDA committee backs Affymax CKD drug

09-12-2011

The US Food and Drug Administration’s Oncologic Drugs Advisory Committee (ODAC) voted 15 to one,…

AffymaxNephrology and HepatologyNorth AmericaOncologypeginesatidePharmaceuticalRegulationTakeda Pharmaceuticals

26 to 41 of 41 results

Parexel

Parexel

Back to top